Kennox: Why we are backing gold and oil in 2016

clock • 2 min read

2016 could turn out to be an interesting year for equities but investors will need patience, commitment and steady nerves in large doses, according to Charles L. Heenan, investment director at Kennox.

Six years into a bull market and value has become unloved. With markets narrowing towards the end of 2015 - a select group of stocks (the 'nifty-nine') drove returns while the overall US market remained flat - some are questioning whether growth and momentum have run their course. 2016 could turn out to be an interesting year for equities and it is evident that investors will need patience, commitment and steady nerves in large doses. As value investors we are comfortable buying unloved, yet excellent companies. A couple of examples to highlight are energy and gold - important sectors...

To continue reading this article...

Join Investment Week for free

  • Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
  • Get ahead of regulatory and technological changes affecting fund management
  • Important and breaking news stories selected by the editors delivered straight to your inbox each day
  • Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
  • Be the first to hear about our extensive events schedule and awards programmes

Join now

 

Already an Investment Week
member?

Login

More on Specialist

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

Deep Dive: Thematics offer diversification but investors must consider bond sensitivity

‘Dedicated specialists’

James Baxter-Derrington
clock 06 April 2023 • 4 min read
European private equity yet to spend €270bn worth of capital

European private equity yet to spend €270bn worth of capital

Deployment of capital expected

Kathleen Gallagher
clock 04 January 2023 • 1 min read
Early-stage biopharma: An opportunity for strategic investment

Early-stage biopharma: An opportunity for strategic investment

Disproportionately smaller investment

Ali H. Munawar
clock 10 August 2022 • 4 min read
Trustpilot